R&D | January 14, 2026
Zealand Pharma taps Denmark’s supercomputer to supercharge drug discovery
Gefion, powered entirely by renewable energy, boasts more than 1,500 NVIDIA GPUs
Gefion, powered entirely by renewable energy, boasts more than 1,500 NVIDIA GPUs
BFF provides bookable fermentation upscaling capacity, process expertise, and quality procedures for pilot campaigns, generating decision-grade data without companies needing to build their own facilities
The acquisition combines Firstsource’s market-leading AI and automation capabilities with TeleMedik’s operational footprint in Puerto Rico
Dr. Reddy’s Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% is an antihistamine eye drop, indicated for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander
This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo to patients in France, Denmark, Iceland, Sweden, Finland and Norway
The multimillion-dollar facility combines discovery and early-phase scale-up capabilities with R&D labs and two pilot plants
Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding
MH002, a rationally designed live microbial consortium, combines six well-characterized commensal strains to target disease-specific mechanisms
The integration unifies brand and field strategy, drives executional alignment, and delivers immediate impact measurement
Vanda strongly disputes the FDA’s reasoning
Subscribe To Our Newsletter & Stay Updated
